Rosa Ruchlemer

Rosa Ruchlemer

Auto-generated profile, based on publicly available information

Rosa Ruchlemer

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2019 in Mycoses
Verified
Journal Article
Closed access
PDF file
RRRosa Ruchlemer
Rosa Ruchlemer
RBRonen Ben-Ami
Ronen Ben-Ami
MBMaskit Bar‐Meir
Maskit Bar‐Meir
JBJennifer R. Brown
Jennifer R. Brown
MMMarion Malphettes
Marion Malphettes
TLTamar Lachish
Tamar Lachish

13 September 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
RRRosa Ruchlemer
Rosa Ruchlemer
MAMichal Amit-Kohn
Michal Amit-Kohn
DRDavid Raveh
David Raveh
Lumír Ondřej HanušLumír Ondřej Hanuš
Lumír Ondřej Hanuš

5 December 2012 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
RRRosa Ruchlemer
Rosa Ruchlemer
APAaron Polliack
Aaron Polliack
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries including Israel, and is less frequent in the Orient, Asia and Middle Eastern Arabic speaking countries. These trends persist in migrants to other countries, continuing into subsequent generations. Biological and genetic disparities have been reported for different ethnic groups. The absence of an association between place of birth and the occurrence of CLL is more in line with a genetic basis for the geographic variations in incidence. Genetic predisposition to CLL is supported by the documented familial aggregation of CLL, with an increased frequency of 8.5-fold among first-degree relatives of patients with CLL and the detection of CLL-like clones in 13.5% of first-degree relatives. It is likely that the development of CLL depends on the interplay of a genetic predisposition with exposure to environmental factors. To better understand the interplay of ethnicity and CLL we reviewed all the available literature on ethnic specific differences for this common form of leukemia.

29 September 2023 in American Journal of Hematology
Verified
Journal Article
Open access
Andrea VisentinAndrea Visentin
Andrea Visentin
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
LSLydia Scarfò
Lydia Scarfò
AKAnargyros Kapetanakis
Anargyros Kapetanakis
CDChristos Demosthenous
Christos Demosthenous
PGPaolo Prospero Ghia
Paolo Prospero Ghia
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including the development of post‐COVID condition. Data from 1540 patients with CLL infected by SARS‐CoV‐2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS‐CoV‐2 variants emergence. Post‐COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4‐month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL‐directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post‐COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post‐COVID. The median time to resolution of the post‐COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS‐CoV‐2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post‐COVID conditions, warranting further investigations.

16 March 2018 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
RRRosa Ruchlemer
Rosa Ruchlemer
MAMichal Amit-Kohn
Michal Amit-Kohn
ATAriella Tvito
Ariella Tvito
ISIrena Sindelovsky
Irena Sindelovsky
AZAri Zimran
Ari Zimran
DRDavid Raveh-Brawer
David Raveh-Brawer

1 February 2020 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
RRRosa Ruchlemer
Rosa Ruchlemer
MMMoshe Mittelman
Moshe Mittelman
AZAri Zimran
Ari Zimran